Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.10% | -14,824.71% | -669.97% | -297.00% | -261.84% |
| Total Depreciation and Amortization | -13.10% | -6.27% | -12.74% | -18.48% | -24.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.98% | 6.87% | -6.37% | -22.20% | -19.37% |
| Change in Net Operating Assets | 235.67% | 129.86% | 192.04% | 141.13% | 68.14% |
| Cash from Operations | -1.34% | -913.91% | -2,608.07% | -596.78% | -421.41% |
| Capital Expenditure | -15.87% | -28.80% | -12.95% | -211.29% | -85.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -582.81% | -1,400.26% | -4.54% | -28.97% | -68.21% |
| Cash from Investing | -590.07% | -1,348.90% | -4.69% | -29.58% | -68.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16,459.67% | 15,305.30% | 6,042.28% | -84.81% | -55.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16,426.99% | 15,274.89% | 6,042.28% | -84.81% | -55.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.07% | 262.63% | 325.30% | -159.90% | -183.48% |